Healthcare Industry News: Hydroxyapatite
News Release - April 4, 2006
MIV Therapeutics Appoints Nationally Ranked Wall Street Medical Device Analyst and Industry Authority Mark Landy as PresidentLandy to Bring Strong Institutional Investment and Business Development Background
VANCOUVER, British Columbia--(HSMN NewsFeed)--April 4, 2006--MIV Therapeutics (OTCBB:MIVT ; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has appointed nationally recognized Wall Street medical device analyst and industry authority Mark Landy as President of the Company.
Dr. Landy is widely recognized for his financial acumen and proven accomplishments as a Wall Street equity analyst with diverse sell-side, buy-side and venture capital experience. He most recently distinguished himself as the Senior Research Analyst of Medical Supplies and Devices at Susquehanna Financial Group, where he was voted the firm's top-ranked healthcare analyst by institutional clients in both 2004 and 2005.
In addition, Dr. Landy is a familiar financial pundit in the financial media, who has made frequent appearances on CNBC, Reuters, Dow Jones, Bloomberg, and in The Wall Street Journal and Business Week, among other outlets. Among other highlights in Dr. Landy's career, he was Director and Senior Research Analyst of Medical Devices at the Boston, MA-based healthcare boutique, Leerink Swann & Company. During his tenure at Leerink Swann the Firm's Medical Supplies and Device Team achieved the #1 ranking in Institutional Investor Magazine's "Best of the Boutiques: Medical Supplies and Devices" poll for both 2002 and 2003.
Dr. Landy holds a degree in business from the Wharton School of Business at the University of Pennsylvania, and also holds the degree equivalent of Doctor of Dental Surgery from the University of the Witwatersrand, in Johannesburg, South Africa. He spent three years in London, U.K., in private practice focusing on post-traumatic facial reconstructive surgery. He has had articles published in both business and health care journals.
Dr. Landy will assume the position of President at MIVT on April 1, 2006, according to Alan Lindsay, Chairman and CEO of MIV Therapeutics. His primary mission will be to further strengthen and accelerate internal procedures as the Company continues to move its advanced medical technologies to market, as well as to raise MIVT's overall profile within the institutional investor community.
"Mark's appointment comes at a crucial time in MIVT's corporate development," said Mr. Lindsay. "He joins us as the Company expands its programs to bring potentially transformative solutions to the high-growth cardiovascular treatment marketplace, as well other high-growth areas. Mark brings a wealth of industry and physician relationships that will be used to significantly raise the company's profile. These relationships will enable the Company to optimize and accelerate the development of key strategic partnerships."
"In Mark's extensive career as a Wall Street analyst on both the sell- and buy-sides, and with his exemplary healthcare background, he has been able to consistently identify major therapeutic trends and emerging growth opportunities early," said Mr. Lindsay. "He has the knowledge and perspective to bring a medical product to market successfully, so that we can take full advantage of all of our proprietary technologies."
Mr. Lindsay added, "During the last decade, Mark has analyzed and invested very successfully in major medical markets such as interventional cardiology, which is a key area of our own technology focus. As a nationally-ranked analyst, he is well-known to institutional investors on Wall Street. We feel privileged to welcome him to our management team and will benefit tremendously from his in-depth knowledge and proven track record."
"I am extremely excited to join the MIVT team, which has already distinguished itself through superior research and development," said Dr. Landy. "I believe MIVT's numerous proprietary technologies hold the potential for revolutionary clinical advances. It is my opinion that the Company's pioneering biocompatible stent coatings, drug delivery systems and other technologies should yield clinically valuable products that will address enormous global opportunities and drive significant revenue growth."
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called Hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Source: MIV Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.